Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) - Total Assets

Latest as of March 2026: CN¥3.01 Billion CNY ≈ $439.90 Million USD

Based on the latest financial reports, Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) holds total assets worth CN¥3.01 Billion CNY (≈ $439.90 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Jilin Jian Yisheng Pharmaceutical Co Ltd - Total Assets Trend (2006–2025)

This chart illustrates how Jilin Jian Yisheng Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 002566 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Jilin Jian Yisheng Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Jilin Jian Yisheng Pharmaceutical Co Ltd's total assets of CN¥3.01 Billion consist of 81.0% current assets and 19.0% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 2.2%
Accounts Receivable CN¥158.33 Million 5.4%
Inventory CN¥1.58 Billion 53.4%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥108.66 Million 3.7%
Goodwill CN¥1.91 Million 0.1%

Asset Composition Trend (2006–2025)

This chart illustrates how Jilin Jian Yisheng Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Jilin Jian Yisheng Pharmaceutical Co Ltd's current assets represent 81.0% of total assets in 2025, an increase from 70.6% in 2006.
  • Cash Position: Cash and equivalents constituted 2.2% of total assets in 2025, down from 8.6% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2006.
  • Asset Diversification: The largest asset category is inventory at 53.4% of total assets.

Jilin Jian Yisheng Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Jilin Jian Yisheng Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Ascendis Pharma AS
NASDAQ:ASND
USA $2.01 Billion
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $8.59 Billion
Spyre Therapeutics Inc.
NASDAQ:SYRE
USA $763.95 Million
3SBio Inc
F:83B
Germany €36.25 Billion
Soleno Therapeutics Inc
NASDAQ:SLNO
USA $608.39 Million
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
China CN¥4.48 Billion
Novavax Inc
NASDAQ:NVAX
USA $1.04 Billion
BB Biotech AG
SW:BION
Switzerland CHF2.64 Billion

Jilin Jian Yisheng Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 5.86 5.85 4.94
Quick Ratio 2.10 1.96 1.17
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥2.04 Billion CN¥2.01 Billion CN¥1.69 Billion

Jilin Jian Yisheng Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Jilin Jian Yisheng Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.23
Latest Market Cap to Assets Ratio 0.11
Asset Growth Rate (YoY) -0.4%
Total Assets CN¥2.96 Billion
Market Capitalization $311.88 Million USD

Valuation Analysis

Below Book Valuation: The market values Jilin Jian Yisheng Pharmaceutical Co Ltd's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Jilin Jian Yisheng Pharmaceutical Co Ltd's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual total assets of Jilin Jian Yisheng Pharmaceutical Co Ltd from 2006 to 2025.

Year Total Assets Change
2025-12-31 CN¥2.96 Billion
≈ $433.09 Million
-0.37%
2024-12-31 CN¥2.97 Billion
≈ $434.70 Million
-2.50%
2023-12-31 CN¥3.05 Billion
≈ $445.83 Million
+2.70%
2022-12-31 CN¥2.97 Billion
≈ $434.11 Million
+3.57%
2021-12-31 CN¥2.86 Billion
≈ $419.15 Million
+2.44%
2020-12-31 CN¥2.80 Billion
≈ $409.16 Million
+12.00%
2019-12-31 CN¥2.50 Billion
≈ $365.32 Million
-2.22%
2018-12-31 CN¥2.55 Billion
≈ $373.60 Million
-3.78%
2017-12-31 CN¥2.65 Billion
≈ $388.29 Million
-0.65%
2016-12-31 CN¥2.67 Billion
≈ $390.81 Million
+1.40%
2015-12-31 CN¥2.63 Billion
≈ $385.40 Million
+5.76%
2014-12-31 CN¥2.49 Billion
≈ $364.42 Million
+31.72%
2013-12-31 CN¥1.89 Billion
≈ $276.66 Million
+13.75%
2012-12-31 CN¥1.66 Billion
≈ $243.23 Million
+5.29%
2011-12-31 CN¥1.58 Billion
≈ $231.00 Million
+206.49%
2010-12-31 CN¥515.06 Million
≈ $75.37 Million
+20.44%
2009-12-31 CN¥427.66 Million
≈ $62.58 Million
+23.13%
2008-12-31 CN¥347.32 Million
≈ $50.82 Million
+1.65%
2007-12-31 CN¥341.67 Million
≈ $50.00 Million
+1.07%
2006-12-31 CN¥338.04 Million
≈ $49.47 Million
--

About Jilin Jian Yisheng Pharmaceutical Co Ltd

SHE:002566 China Biotechnology
Market Cap
$311.88 Million
CN¥2.13 Billion CNY
Market Cap Rank
#14723 Global
#4394 in China
Share Price
CN¥6.44
Change (1 day)
-0.92%
52-Week Range
CN¥6.44 - CN¥9.05
All Time High
CN¥19.38
About

Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprisi… Read more